Navigation Links
University Hospitals Case Medical Center cardiologists discover cancer risks in blood pressure meds
Date:6/13/2010

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

This class of drugs is used by millions of patients not only for high blood pressure but also for heart failure, cardiovascular risk reduction and diabetic kidney disease.

University Hospitals Harrington-McLaughlin Heart & Vascular Institute's Drs. Ilke Sipahi, Daniel I. Simon and James C. Fang recently completed a meta-analysis of over 60,000 patients randomly assigned to take either an ARB or a control medication. Their findings are published online today at The Lancet Oncology.

The researchers found that patients randomized to ARBs has "significantly increased risk of new cancer" compared to control patients.

"We have found the risk of new cancers was increased with these medications by 8-11 percent," said Dr. Ilke Sipahi, associate director of heart failure and transplantation and assistant professor at Case Western Reserve University School of Medicine. "Most importantly, risk of lung cancer was increased by 25 percent."

However, the research did not establish any link between ARBs and other types of cancer such breast cancer.

"This is the first time an association between ARBs and cancer development is suggested," Dr. Sipahi continued. "While our findings are robust, they need to be replicated in other studies before they can be considered as definitive."

Before this study, there were no major safety concerns with ARBs except for their use in pregnancy and in patients with chronic kidney or blockages of kidney arteries. Interestingly, previous animal studies with ARBs have been negative for cancer development.

"In medicine, physicians must balance the benefits and risks of all drug and device therapies," said Dr. Daniel Simon, director of the Harrington-McLaughlin Heart & Vascular Institute at University Hospitals Case Medical Center and professor at Case Western Reserve University School of Medicine. "We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the treatment of high blood pressure and heart failure. Meta-analyses are a powerful tool to look at low frequency safety signals, but require confirmation with other approaches, such as large national health and managed care registries."


'/>"/>

Contact: Mike Ferrari
mike.ferrari@uhhospitals.org
216-844-7239
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. University of Pennsylvania: Contrary to popular models, sugar is not burned by self-control tasks
2. Collagen manufactured from transgenic tobacco plants at Hebrew University
3. "How Facebook Makes Lonely People Even Lonelier" Revealed by Distinguished University of Chicago Professor in Interview with Brian Vaszily on IntenseExperiences.com
4. University Hospitals Case Medical Center experts present at ASCO Annual Meeting
5. Louisiana's First DNP Program Kicks Off Classes at Loyola University New Orleans
6. Maastricht University Medical Centre Advances Cranial Implant Technology with PEEK-OPTIMA
7. University of Minnesota, Mayo Clinic sign research pact with Karolinska
8. New research at the University of Leicester links shoplifting to your personality
9. University of Colorado Hospital Moving Forward with $400 Million Expansion
10. University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation
11. Center for the Study of Aging established at University of Denver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency ... Belmont, and Palo Alto, is proud to announce an important upgrade to its geographic ... for home care close to home, and by having city-specific pages, NuevaCare is answering ...
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 27, 2017  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), ... of select chronic diseases utilizing its ProNeura™ long-term, ... U.S. Food & Drug Administration (FDA) has completed ... New Drug Application (IND) and has requested that ... pending submission of the requested information and the ...
(Date:2/28/2017)... Md. and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that Martine ... Therapeutics, will provide an overview and update on the company,s ... Health Care Conference in Boston, Massachusetts . ... 6, 2017, at 2:00 PM Eastern Time, and can be ...
(Date:2/28/2017)... Feb. 27, 2017 This report provides all ... its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
Breaking Medicine Technology: